-+ 0.00%
-+ 0.00%
-+ 0.00%
Jiuzhitang announced on November 19 that the company's shareholding company, Beijing Kexin Meide Biomedical Technology Co., Ltd., and its affiliate company, Wallardzumab Injection, a Class 1 innovative antibody targeting glucagon receptors, recently obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of this product in type 1 diabetics in China. Indications: Subcutaneous injection once a week as an adjuvant treatment for insulin. It is suitable for treating type 1 diabetes in adults who cannot achieve target blood sugar with insulin alone.
Share
Listen to the news
Jiuzhitang announced on November 19 that the company's shareholding company, Beijing Kexin Meide Biomedical Technology Co., Ltd., and its affiliate company, Wallardzumab Injection, a Class 1 innovative antibody targeting glucagon receptors, recently obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of this product in type 1 diabetics in China. Indications: Subcutaneous injection once a week as an adjuvant treatment for insulin. It is suitable for treating type 1 diabetes in adults who cannot achieve target blood sugar with insulin alone.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending